References
- Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc. Drugs Ther. 19(6), 403–414 (2005).
- Vandenberg BF, Robinson J. Management of the patient with statin intolerance. Curr. Atheroscler. Rep. 12(1), 48–57 (2010).
- Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J. Am. Coll. Cardiol. 49(23), 2231–2237 (2007).
- Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim. Biophys. Acta 1126(3), 247–254 (1992).
- Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J. Clin. Pharmacol. 30(7), 596–608 (1990).
- Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs 8(6), 373–418 (2008).
- Rundek T, Naini A et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 61, 889–892 (2004).
- Ghirlanda G, Oradei A, Manto A et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. 33(3), 226–229 (1993).
- Fukami M, Maeda N, Fukushige J et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res. Exp. Med. (Berl.) 193(5), 263–273 (1993).
- De Pinieux G, Chariot P, Ammi-Saïd M et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol. 42(3), 333–337 (1996).
- Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol. Aspects Med. 18(Suppl.), S137–S144 (1997).
- Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption. Am. J. Cardiol. 98(5), 705–706 (2006).
- Link E, Parish S, Armitage J et al.; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med. 359(8), 789–799 (2008).
- König J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol. 372(6), 432–443 (2006).
- Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17), 1609–1616 (2009).
- Caso G, Kelly P, McNurlan MA et al. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 99(10), 1409–1412 (2007).
- Young JM, Florkowski CM, Molyneux SL et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am. J. Cardiol. 100(9), 1400–1403 (2007).
- Vladutiu G, Isackson P, Wortmann R et al. Metabolic muscle disorders and cholesterol-lowering drugs. Abstracts of: The American College of Rheumatology 2004 meeting. San Antonio, TX, USA, 16–21 October 2004 (Abstract 1784).
- Parker BA, Augeri AL, Capizzi JA et al. Effect of statins on creatine kinase levels before and after a marathon run. Am. J. Cardiol. 109(2), 282–287 (2012).
- Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clin. Ther. 30(2), 294–306 (2008).
- Keech A, Simes RJ, Barter P et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849–1861 (2005).
- Keech A, Drury P, Davis TM et al. Protection against nephropathy with fenofibrate in Type 2 diabetes mellitus: the FIELD Study. Circulation 120, S419–S420 (2009).
Patents
- Merck & Co Inc.: US4933165 (1990).
- Merck & Co Inc.: US4929437 (1990).